AMGN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

375.250

Open

374.280

VWAP

369.90

Vol

1.98M

Mkt Cap

198.67B

Low

366.360

Amount

733.76M

EV/EBITDA(TTM)

14.20

Total Shares

539.71M

243.06B

EV/OCF(TTM)

22.60

P/S(TTM)

5.34

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Events Timeline

(ET)

2026-06-29

15:30:00

New England Journal of Medicine Retracts Amgen Tavneos Clinical Trial Paper

2026-06-25 (ET)

2026-06-25

16:30:00

Nasdaq Declines Despite Strong Micron Earnings Report

2026-06-25

12:30:00

Major Averages Mixed at Noon, Nasdaq Declines

2026-06-25

06:30:00

FDA Accuses ChemoCentryx of Manipulating Tavneos Study Data

News

4.5

07-06Fool

Chip Stocks Lead Market Rally Amid Mixed Index Performance

8.5

07-04NASDAQ.COM

Honeywell Reinvents Automation Business Post-Spinoff

8.5

07-04Fool

Dow Jones Welcomes Alphabet Amid Strategic Shifts

9.0

07-03NASDAQ.COM

Roche's Divarasib Shows Positive Results in Late-Stage Study

8.5

06-30Fool

Alphabet Joins Dow Jones, Boosting Market Focus

9.5

06-30NASDAQ.COM

Cisco Systems Reports Strong Growth Driven by AI Platform

24 Analyst Rating

Wall Street analysts forecast AMGN stock price to rise

14 Buy

9 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

280.00

Averages

363.10

High

425.00

Current: 0.000

Low

280.00

Averages

363.10

High

425.00

Truist

Hold

maintain

$327 -> $340

AI Analysis

2026-07-07

New

Reason

Truist

Price Target

$327 -> $340

AI Analysis

2026-07-07

New

maintain

Hold

Reason

Truist raised the firm's price target on Amgen to $340 from $327 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within its coverage, the analyst tells investors in a research note. Truist adds that it sees a robust catalyst calendar, supported by sector optimism and deal activity, as drivers for the recent momentum across the sector.

Mizuho

Salim Syed

Neutral

maintain

$295 -> $303

2026-06-16

Reason

Mizuho

Salim Syed

Price Target

$295 -> $303

2026-06-16

maintain

Neutral

Reason

Mizuho analyst Salim Syed raised the firm's price target on Amgen to $303 from $295 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q1 report.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AMGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Amgen Inc (AMGN.O) is 16.81, compared to its 5-year average forward P/E of 14.16. For a more detailed relative valuation and DCF analysis to assess Amgen Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

14.16

Current PE

16.81

Overvalued PE

15.38

Undervalued PE

12.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.45

Current EV/EBITDA

13.52

Overvalued EV/EBITDA

11.66

Undervalued EV/EBITDA

9.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.72

Current PS

5.11

Overvalued PS

5.07

Undervalued PS

4.36

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks low shorts under 50 k

Intellectia · 492 candidates

Region: USShort Ratio: LessThan10PctList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

JPM

JPMorgan Chase & Co

882.60B

ABBV

Abbvie Inc

449.31B

HSBC

HSBC Holdings PLC

326.39B

AMGN

Amgen Inc

194.59B

UBS

UBS Group AG

162.22B

SCHW

Charles Schwab Corp

157.69B

stocks with zero short shares available

Intellectia · 492 candidates

Region: USShort Ratio: LessThan10PctList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

JPM

JPMorgan Chase & Co

882.60B

ABBV

Abbvie Inc

449.31B

HSBC

HSBC Holdings PLC

326.39B

AMGN

Amgen Inc

194.59B

UBS

UBS Group AG

162.22B

SCHW

Charles Schwab Corp

157.69B

Elite pharma

Intellectia · 9 candidates

Sector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchIndustry: Biotechnology & Medical Research, PharmaceuticalsPrice: >= $-100.00Volume: >= -100Themes: Medical Instruments & Supplies, Genomics, Cancer Research, BiotechRsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Ema 20: >= -100Ema 60: >= -100Weekly Average Dollar Volume: >= -100

Ticker

Name

Market Cap$

JNJ

Johnson & Johnson

570.51B

ABBV

AbbVie Inc

398.27B

MRK

Merck & Co Inc

295.39B

AMGN

Amgen Inc

185.96B

VRTX

Vertex Pharmaceuticals Inc

113.14B

BIIB

Biogen Inc

29.39B

nasdaq

Intellectia · 45 candidates

Analyst Consensus: Moderate Buy, Strong BuyList Exchange: XNASTarget Price Upside Potential: AbovePrice, MoreAbovePriceIs Optionable: TrueIs Index Component: NDX

Ticker

Name

Market Cap$

NVDA

NVIDIA Corp

4.96T

MSFT

Microsoft Corp

3.10T

AMZN

Amazon.com Inc

2.65T

AVGO

Broadcom Inc

1.83T

META

Meta Platforms Inc

1.51T

NFLX

Netflix Inc

346.04B

then do u have other alternative stock

Intellectia · 8 candidates

Market Cap: >= 5.00BThemes: BiotechAnalyst Consensus: Moderate Buy, Strong BuyMoving Average Relationship: PriceAboveMA200Is Optionable: True

Ticker

Name

Market Cap$

AMGN

Amgen Inc

181.47B

GILD

Gilead Sciences, Inc

160.88B

VRTX

Vertex Pharmaceuticals Inc

110.90B

REGN

Regeneron Pharmaceuticals Inc

73.20B

BIIB

Biogen Inc

28.49B

INCY

Incyte Corp

19.04B

acciones EEUU

Intellectia · 341 candidates

Region: USMarket Cap Category: largeRelative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC, RUT, DJI, NDX

Ticker

Name

Market Cap$

NEE

Nextera Energy Inc

198.92B

Verizon Communications Inc

198.09B

DIS

Walt Disney Co

187.65B

Boeing Co

181.25B

AMGN

Amgen Inc

178.70B

STX

Seagate Technology Holdings PLC

176.34B

yes stocks

Intellectia · 27 candidates

Market Cap: >= 50.00BDividend Yield Ttm: 2.50 - 6Analyst Consensus: Strong Buy, Moderate BuyBeta: LowRiskRevenue 5yr Cagr: >= 7

Ticker

Name

Market Cap$

XOM

Exxon Mobil Corp

618.95B

CVX

Chevron Corp

368.92B

Coca-Cola Co

329.83B

UNH

UnitedHealth Group Inc

322.34B

MRK

Merck & Co Inc

276.38B

Philip Morris International Inc

255.91B

what stock should buy

Intellectia · 96 candidates

Market Cap: >= 10.00BQuarter Eps Yoy Growth: >= 5.0%Pe Ttm: 10 - 35Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

GOOG

Alphabet Inc

4.11T

AAPL

Apple Inc

3.97T

AMZN

Amazon.com Inc

2.69T

JPM

JPMorgan Chase & Co

832.27B

Micron Technology Inc

513.20B

BAC

Bank of America Corp

384.37B

what stock to buy

Intellectia · 93 candidates

Market Cap: >= 10.00BQuarter Eps Yoy Growth: >= 5.0%Pe Ttm: 10 - 35Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

GOOG

Alphabet Inc

3.86T

AAPL

Apple Inc

3.81T

AMZN

Amazon.com Inc

2.58T

JNJ

Johnson & Johnson

573.15B

Micron Technology Inc

481.05B

BAC

Bank of America Corp

381.22B

large cap taht is basing

Intellectia · 14 candidates

Market Cap: >= 10.00BRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Month Price Change Pct: $-5.00 - $5.00Support Resistance Relationship: PriceAroundSupport

Ticker

Name

Market Cap$

JNJ

Johnson & Johnson

574.36B

AMGN

Amgen Inc

189.44B

PFE

Pfizer Inc

153.13B

WMB

Williams Companies Inc

88.95B

WBD

Warner Bros Discovery Inc

68.79B

TAK

Takeda Pharmaceutical Co Ltd

57.12B

Whales Holding AMGN

PRIMECAP Management Company

Beacon Investment Advisory Services, Inc.

Security Investors, LLC

Invesco Capital Management LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Amgen Inc (AMGN) stock price today?

The current price of AMGN is 368.1 USD — it has increased 0.45

What is Amgen Inc (AMGN)'s business?

What is the price predicton of AMGN Stock?

Wall Street analysts forecast AMGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is363.10 USD with a low forecast of 280.00 USD and a high forecast of 425.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.